Oric Pharmaceuticals Inc（ORIC）财务数据ORICOric Pharmaceuticals Inc

Evaluating the bottom line, ORIC Pharmaceuticals, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -39.80%, provide a clear picture of how effectively ORIC converts its operational activities into shareholder value.

In the context of the broader market, ORIC competes directly with industry leaders such as NBTX and OCUL. With a market capitalization of $928.21M, it holds a significant position in the sector. When comparing efficiency, ORIC's gross margin of N/A stands against NBTX's 100.00% and OCUL's 85.08%. Such benchmarking helps identify whether ORIC Pharmaceuticals, Inc. is trading at a premium or discount relative to its financial performance.

The company has a current ratio of 13.19, indicating strong liquidity, and cash reserves of $387.6 million, which can fund operations into the second half of 2028.